| Name | Title | Contact Details |
|---|
The Adjuvant Group is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cadence Science is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More commonly known as Columbia County Health System and Dayton General Hospital, the Columbia County Public Hospital District #1 was established in 1960 with the vision and mission of providing high quality healthcare to our local communities. We are a 25-bed, Critical Access Hospital with Level V Trauma Center, Level III Cardiac and Stroke Center designations. Additionally, we are the regions primary wound care and hyperbaric therapy treatment center. Our primary service areas include Dayton, Waitsburg, Starbuck, and the surrounding region. We are comprised of Columbia Family Clinic, Waitsburg Clinic, Booker Rest Home, and Dayton General Hospital with our Rural Health Clinics open for primary care and behavior health services 6 days a week. We are fully staffed with 3 primary care medical doctors, a board-certified emergency medicine doctor, a board-certified pediatrician, 4 mid-level family practice providers, and dermatology focused ARNP. Our Emergency Department is staffed with our employed providers as well as partner physicians. In addition to Acute Care services, we offer inpatient care for sub-acute, Swing Bed patients, which are patients that need a step down from acute care, but still require skilled nursing care and/or various rehabilitation therapies for an extended period. This service allows patients, who may have had a qualifying, Acute hospitalization or surgery, to return to our facility and receive hospital class nursing and rehabilitation services for an extended period.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Isto Technologies, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Saint Louis, MO. To find more information about Isto Technologies, Inc, please visit www.istotech.com